Efficacy and safety of the anti-IL1RAP antibody nadunolimab (CAN04) in combination with gemcitabine and nab-paclitaxel in patients with advanced/metastatic pancreatic cancer.

Auteurs

Van Cutsem E, Collignon J, Eefsen RL, Ochsenreither S, Zvirbule Z, Ivanauskas A, Arnold D, Baltruskeviciene E, Pfeiffer P, Yachnin J, Magnusson S, Rydberg Millrud C, Sanfridson A, Losic N, Garcia-Ribas I, Tersago D, Awada A

  • Date de publication

    October 2024

  • Type

    Article

  • Review

    Clin Cancer Res

  • Researcher's name

    AWADA AHMAD HUSSEIN

  • Hôpital

    Institut Jules Bordet

  • Service

    Médecine Oncologique

  • PMID

    39385434

  • DOI

    10.1158/1078-0432.CCR-24-0645